J&J seeks approval of Darzalex for early-stage multiple myeloma

Microscopic view of bone marrow slide showing Multiple myeloma, also known as myeloma, is a type of bone marrow cancer.

Md Saiful Islam Khan/iStock via Getty Images

  • Johnson & Johnson (NYSE:JNJ) has submitted applications to drug regulators in the U.S. and EU seeking approval of, respectively, Darzalex Faspro (daratumumab and hyaluronidase-fihj) and Darzalex (daratumumab) for a type of early-stage multiple myeloma.
  • The healthcare giant is seeking approval

Leave a Reply

Your email address will not be published. Required fields are marked *